Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

NCT01896102 is registered in ClinicalTrials.gov with Genetix Biotherapeutics Inc. as lead sponsor.

NCT NCT01896102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Lead sponsor
Genetix Biotherapeutics Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
August 21, 2013
Completion date
March 26, 2021
Enrollment
32 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral adrenoleukodystrophy (cald)